当前位置： SCI文献检索 > VACCINE期刊下所有文献 > The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

Abstract：

BACKGROUND:New, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31 adjuvant. We assessed the safety and immunogenicity of H4:IC31 in South African adults from a TB endemic setting. METHODS:In this double blind, placebo controlled, phase I trial, Mycobacterium tuberculosis-uninfected, HIV-uninfected, healthy adults with a history of childhood BCG vaccination were randomly allocated to two intramuscular vaccinations with 5, 15, 50 or 150 μg H4 formulated in 500nmol IC31, two months apart. Vaccinees were followed for six months to assess safety; immunogenicity was measured by ELISpot and intracellular cytokine staining assays. RESULTS:Thirty-two participants received H4:IC31 and 8 received placebo. Injection site adverse events were common but mild; mild fatigue was the most common systemic adverse event. Frequencies of adverse events did not differ between dosage groups. Detectable antigen-specific CD4 T cell responses were induced by all doses of H4:IC31, but doses below 50 μg induced the highest frequencies of CD4 T cells, comprised predominantly of IFN-γ(+)TNF-α(+)IL-2(+) or TNF-α(+)IL-2(+) cells. These memory responses persisted up to the end of follow up, on study day 182. CONCLUSIONS:H4:IC31 demonstrated an acceptable safety profile and was immunogenic in South African adults. In this trial, the 15 μg dose appeared to induce the most optimal immune response.

journal_name

Vaccine

journal_title

Vaccine

authors

Geldenhuys H,Mearns H,Miles DJ,Tameris M,Hokey D,Shi Z,Bennett S,Andersen P,Kromann I,Hoff ST,Hanekom WA,Mahomed H,Hatherill M,Scriba TJ,H4:IC31 Trial Study Group.,van Rooyen M,Bruce McClain J,Ryall R,de Bruyn G,H4:

doi

10.1016/j.vaccine.2015.05.036

subject

Has Abstract

pub_date

2015-07-09 00:00:00

pages

3592-9

issue

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(15)00688-X

journal_volume

pub_type

杂志文章,随机对照试验

在线工具

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.